2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

2:30PM-4:00PM: Abstract Number: 2081

The SLE Workshop: An Evaluation of a Long-Standing Hospital-Based Psychoeducational Program

ARHP II: Lupus

2:30PM-4:00PM: Abstract Number: 2063

The Survival Impact of Statins in Psoriasis and Psoriatic Arthritis: A General Population-Based Cohort Study

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Clinical Aspects

2:30PM-4:00PM: Abstract Number: 2013

TIARP Attenuates Autoantibody-Mediated Arthritis Via the Suppression of Neutrophil Infiltration into the Joint

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

2:30PM-4:00PM: Abstract Number: 2012

TNF Confers Pathogenic Memory in Synovial Fibroblasts Via Chromatin Remodeling, NF-Kb-Dependent Transcription and MAPK-Mediated mRNA Stabilization

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

2:30PM-4:00PM: Abstract Number: 2031

Tuberculosis in Patients Treated with Biological Drugs

Infection-related Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 2059

Tumor Necrosis Factor Inhibitor Tapering Induced Radiographic Progression Is Driven By Weighted Mean Disease Activity over Time, Not Flaring or Lower TNFi Exposition

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy III: Biosimilars

2:30PM-4:00PM: Abstract Number: 2061

Uncovering Crohn’s Disease in Patients with Spondyloarthropathies Using Videocapsule Endoscopy

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Clinical Aspects

2:30PM-4:00PM: Abstract Number: 2070

Urinary Biomarker Based “a-RAIL”� Study in Adults with Lupus Nephritis

Systemic Lupus Erythematosus - Clinical Aspects and Treatment III: Biomarkers

2:30PM-4:00PM: Abstract Number: 2071

Urinary Osteoprotegerin As Biomarker of Lupus Nephritis Disease Activity: Cross Sectional and Longitudinal Study

Systemic Lupus Erythematosus - Clinical Aspects and Treatment III: Biomarkers

2:30PM-4:00PM: Abstract Number: 2065

Verification of Novel Soluble Biomarkers That Differentiate Patients with Psoriatic Arthritis from Those with Psoriasis without Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Clinical Aspects

2:30PM-4:00PM: Abstract Number: 2008

WISP1 Aggravates Osteoarthritis By Modulation of TGF-β Signaling and Positive Regulation of Canonical Wnt Signaling

Biology and Pathology of Bone and Joint: Ostearthritis Pathogenesis

4:30PM-6:00PM: Abstract Number: 2171

A Comparison of Maternal Outcomes in Women with and without Juvenile Idiopathic Arthritis

ARHP III: Epidemiology and Public Health

4:30PM-6:00PM: Abstract Number: 2122

A Novel Severity Score Based on Cardiac Neonatal Lupus Manifestations Serves As a Predictor and Outcome Measure of Morbidity in Anti-Ro Exposed Fetuses

Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects

4:30PM-6:00PM: Abstract Number: 2108

A Pragmatic Cluster-Randomized Controlled Trial of an Automated, Pharmacy-Based Intervention to Optimize Allopurinol Therapy in Gout

Metabolic and Crystal Arthropathies I: Therapeutics

4:30PM-6:00PM: Abstract Number: 2143

A Safety Analysis of Tofacitinib 5mg Twice Daily Administered As Monotherapy or in Combination with Background Conventional Synthetic Dmards in a Phase 3 Rheumatoid Arthritis Population

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy IV: Safety of Targeted Therapies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].